5月20日，Roivant Sciences盘前上涨8.12%，报30.43美元/股，成交额170.13万美元。
消息面上，公司公布了截至3月31日的第四财季及全年财务业绩。数据显示，第四财季持续运营每股收益为0.28美元，营收252万美元低于市场预期的382万美元。尽管营收不及预期，但公司同步披露的业务动态更新获得市场积极反应，推动股价走强。此前机构预期本季度营收将大幅下滑，公司产品收入为主要营收来源，上季度达2,093.60万美元，占比超84%。
Roivant Sciences是一家注册于百慕大的生物制药公司，通过构建技术平台和培养人才推出专注的生物制药及健康技术子公司，致力于更快开发变革性药物。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.